1-3 of 3
Idalia Liboy, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL).

Maribel Cotto, MD, Fernando Cabanillas, MD, Idalia Liboy, MD, Ezequiel Rivera, MD, Orestes A. Pavia, MD, Margarita Bruno
Journal: Blood
Blood (2010) 116 (21): 2789.
https://doi.org/10.1182/blood.V116.21.2789.2789
Published: 2010
Journal Articles

A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas

Jennifer L. Cultrera, MD, Jijun Liu, MD, Idalia Liboy, MD, Celeste M. Bello, MD, Lubomir Sokol, MD, PhD, Eduardo M. Sotomayor, MD, Enrique Santana, RN, Fernando Cabanillas, MD
Journal: Blood
Blood (2010) 116 (21): 2879.
https://doi.org/10.1182/blood.V116.21.2879.2879
Published: 2010
Journal Articles

Very Early Post-Treatment PET/CT Scan Performed One Week after First Chemotherapy Course Compared Against the Standard PET after Third Course in Histologically Aggressive Lymphoma (NHL).

Fernando Cabanillas, MD, Jorge Toro, MD, Jorge W. Perdomo, MD, Idalia Liboy, MD, Orestes Pavia, MD, Norman Maldonado, MD, Ezequiel Rivera, MD
Journal: Blood
Blood (2006) 108 (11): 2433.
https://doi.org/10.1182/blood.V108.11.2433.2433
Published: 2006